XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, raised an additional $318.8 million through a Series C financing round to bring drug development into the future.
Switzerland’s Roche acquired genetic sequencing company Stratos Genomics for an undisclosed amount.
The U.S. Food and Drug Administration approved AstraZeneca and Merck’s Lynparza (olaparib) in combination with Roche’s Avastin (bevacizumab) for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer has been tested to have either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.
GRAIL published validation data for the company’s multi-cancer early detection blood test, which can detect more than 50 different cancer types across all stages.
A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
Personal Genome Diagnostics Inc. (PGDx) – a leader in cancer genomics – is partnering with Eisai Co. Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology, to be used by Eisai researchers at their Tsukuba Research Laboratory.
In the halls of MD Anderson Cancer Center, Vitrakvi is known for having a “Lazarus effect” in some patients because the drug can reverse late-stage cancer that has defied all other treatment options.
Israel’s Pitango Venture Capital is launching a fund that will reach $150 million to invest in health technology.
The BIO International Convention is being held in Philadelphia from June 3-6, 2019, with more than 16,000 attendees expected from around the world. The convention draws a list of who’s who in drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy, with more than 7,000 companies and 47,000 partnering meetings.
A recent report written by SVB Leerink analysts that looked at eight companies and their research-and-development portfolios found that in the past five years, they progressed only 24 percent of their new molecular entities to approval.